Novo Nordisk has bought back DKK 11.2B in shares as Lilly's retatrutide data piles up
A US judge also denied Novo's bid to block Lilly's weight-loss drug ads, and Andel will offer Wegovy to employers through its marketplace.
Recap by typeshit. Full story at ad-hoc-news.de.